Table 3 The results of metabolome-wide MR on cancers
From: Prioritization of therapeutic targets for cancers using integrative multi-omics analysis
Type | Path | Method | NSNP | OR (95% CI) | P val |
|---|---|---|---|---|---|
Intrahepatic ducts, biliary tract and gallbladder cancer | PWY.5695..urate.biosynthesis.inosine.5..phosphate.degradation | Inverse variance weighted | 8 | 2.77 (1.80–4.26) | 3.30E−06 |
Intrahepatic ducts, biliary tract and gallbladder cancer | UBISYN.PWY..superpathway.of.ubiquinol.8.biosynthesis..prokaryotic | Inverse variance weighted | 15 | 0.72 (0.62–0.84) | 2.37E−05 |
Liver cancer | UBISYN.PWY..superpathway.of.ubiquinol.8.biosynthesis..prokaryotic | Inverse variance weighted | 15 | 0.51 (0.41–0.65) | 2.10E−08 |
Pancreatic cancer | UBISYN.PWY..superpathway.of.ubiquinol.8.biosynthesis..prokaryotic | Inverse variance weighted | 15 | 1.49 (1.31–1.70) | 1.26E−09 |